mTOR in Growth and Protection of Hypertrophying Myocardium

E-ISSN： 1875-6182|7|1|52-63

ISSN： 1871-5257

Source： Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol.7, Iss.1, 2009-01, pp. : 52-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR Inhibitor for the Treatment of Hepatocellular Carcinoma

Digestive Diseases, Vol. 29, Iss. 3, 2011-08 ,pp. : 310-315

Karger

Access to resources Recommend Favorite

mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features

By Sajjad Emir

Endocrine Pathology, Vol. 24, Iss. 1, 2013-03 ,pp. : 11-19

Humana Press, Inc

Access to resources Recommend Favorite

The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells

By Bussiere C. Lakey J. Shapiro A. Korbutt G.

Diabetologia, Vol. 49, Iss. 10, 2006-10 ,pp. : 2341-2349

Springer Publishing Company

Access to resources Recommend Favorite

mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open

By Jardine Meg J. Liyanage Thaminda Buxton Erin Perkovic Vlado

Nephrology Dialysis Transplantation, Vol. 28, Iss. 2, 2013-02 ,pp. : 242-244

Oxford University Press

Access to resources Recommend Favorite

Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition

Liver Cancer, Vol. 1, Iss. 3-4, 2012-11 ,pp. : 247-256

Karger

Access to resources Recommend Favorite